Vivos therapeutics sees positive preliminary metrics following unprecedented fda 510(k) clearance of the company's proprietary oral medical devices to treat severe osa

New dentist inquiries jumped 600% and signed dentist enrollment contracts up 38% sequentially over q3 care oral medical device unit orders increased 26% following fda clearance littleton, colo., jan. 08, 2024 (globe newswire) -- vivos therapeutics, inc. (the “company” or “vivos”) (nasdaq:vvos), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (osa)), is pleased to announce that vivos is seeing positive preliminary metrics following its november 28, 2023 announcement regarding fda 510(k) clearance of its care oral medical devices to treat severe osa.
VVOS Ratings Summary
VVOS Quant Ranking